Nijhawan Pardeep 4

What Happened

• Pardeep Nijhawan, CEO of Edesa Biotech (EDSA), made two purchases on March 2, 2026: 2,000 shares at $2.00 ($4,000) and 1,000 shares at $2.28 ($2,280), for a total acquisition of 3,000 shares costing $6,280. These were reported as purchases (code P) on a Form 4.

Key Details

• Transaction dates and prices: Mar 2, 2026 — 2,000 shares @ $2.00; Mar 2, 2026 — 1,000 shares @ $2.28.
• Total acquired: 3,000 shares for $6,280.
• Filing: Form 4 filed Mar 3, 2026 reporting the Mar 2 transactions — the filing was made the next day and appears timely.
• Shares owned after transaction: Not specified in the provided report.
• Notable footnotes:
  • F1: Some reported shares are held by wholly owned corporations of the reporting person; he disclaims beneficial ownership except to the extent of his pecuniary interest.
  • F2: He is co-trustee of The New Nijhawan Family Trust 2015 and similarly disclaims beneficial ownership except for pecuniary interest.
• No 10b5-1 plan, option exercises, tax withholding, or late-filing flags were indicated in the details provided.

Context

• Code P indicates a straight purchase (open market or private purchase). Purchases by insiders are often watched by investors as a potential sign of confidence, but this particular acquisition is relatively small ($6.3k) and could reflect routine personal investing. The footnotes show some shares are held via related entities/trust, and the reporter disclaims broader beneficial ownership beyond personal pecuniary interest.